- Vitrian commits $50 million, with potential to scale to $65 million, to AmplifyBio’s Ohio-based Manufacturing Enablement Center (AMEC).
- The investment supports AmplifyBio’s advanced therapy manufacturing expansion in Central Ohio’s biomanufacturing corridor.
Vitrian, a provider of investment capital and capacity-building services for biomanufacturing, has announced a $50 million investment in AmplifyBio’s Manufacturing Enablement Center (AMEC) in New Albany, Ohio. This funding, which could extend to $65 million, represents the first phase of Vitrian’s broader plan to advance biomanufacturing capabilities in Central Ohio.
The 350,000-square-foot AMEC facility is strategically located in Ohio’s growing manufacturing corridor, near Intel’s semiconductor mega-fab facility and Amgen’s biomanufacturing site. AmplifyBio, an advanced therapy contract research organisation (CRO) and contract development and manufacturing organisation (CDMO), will use the facility for process development, quality control, and GMP manufacturing of advanced therapies.
Commenting on the partnership, Scott Nudelman, Co-Founder and Managing Principal at Vitrian, said, “We are very excited to make our first investment in Ohio and launch a wider partnership with AmplifyBio. We have been impressed by the creativity and progressive thinking of the AmplifyBio team and look forward to further collaborations.” He noted that the support from local government and institutions in the Columbus area strengthens the appeal of Ohio as a biomanufacturing hub.
AmplifyBio’s CEO, J. Kelly Ganjei, expressed optimism about the partnership, stating, “We chose to partner with Vitrian based on the alignment of our strategic goals for our manufacturing site, and we are hopeful this is the first of many things we can do together.”
Overview of outsourcing trends 
